Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Roche Tries To Pack Illumina’s Board
by Ann M. Thayer
February 6, 2012
| A version of this story appeared in
Volume 90, Issue 6
Roche has taken further steps to gain control of Illumina after the gene-sequencing firm adopted a shareholder rights plan to thwart Roche’s $5.7 billion takeover bid. On Jan. 27, Roche launched a $44.50-per-share tender offer for Illumina. Last week, it announced plans to nominate directors for election at Illumina’s 2012 annual meeting in an attempt to gain control of the board. Roche still says it prefers to work with Illumina on a merger plan. In response, Illumina CEO Jay T. Flatley has said the board is reviewing Roche’s offer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter